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Increasing treatment rate to 16% showed a decrease of 816/571 DCC and 260/182 HCC 
cases, 74/52 LTs and 655/458 LrDs. The overall reduction in ESLD cases was estimated 
to be -6.1%/-4.2% and -8.8%/-6.1% in both scenarios respectively. ConClusions: A 
1-year increase in treatment rate was predicted to reduce the burden of genotype-1 
CHC in 20 years in the UK. Different treatment rates across Europe imply unequal 
opportunities for patients to prevent CHC sequelae. Identifying CHC patients and 
offering antiviral therapy to maximise SVR could prevent substantial further severe 
liver disease and mortality.
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objeCtives: Approximately 1,000-1,200 people in the United States (US) develop 
meningococcal disease (MD) each year. MD is a life-threatening bacterial infection 
most common in infants (age < 1 year), adolescents, and persons living in close 
quarters. We estimated annual incidence and demographic characteristics of MD 
in the US pediatric population from 2000 to 2009. Methods: Data for pediatric (age 
≤ 20 years) MD-related hospitalizations (discharges with ICD-9-CM 036.xx) from the 
2000, 2003, 2006, and 2009 HCUP Kids’ Inpatient Databases (KID) were retrospec-
tively analyzed. Annual MD incidence per 100,000 pediatrics (adjusted to 2010 US 
population) was estimated using KID sampling weights and year-specific popula-
tion denominators from US census data. Results: Pediatric MD incidence steadily 
decreased from 1.9/100,000 in 2000 to 0.7/100,000 in 2009, a 63% decline. Incidence 
was highest, by far, in infants, which also decreased during 2000-2009 (7.6/100,000 
to 3.8/100,000, a 50% decline). Among children aged 1-4 years, incidence fell from 
2.7/100,000 to 0.8/100,000 during this period, a 70% decline. In children aged 5-10 
years, we observed a 75% decline (1.2/100,000 to 0.3/100,000); similar incidence and 
trends were seen for age groups 11-18 and 19-20 years. Pediatric MD cases were 
predominantly male, with male representation increasing from 55% to 61% of cases 
during 2000-2009. The racial composition of pediatric MD shifted somewhat dur-
ing this period, with representation declining among whites (from 56% to 45% of 
cases) and increasing among blacks (from 8% to 11% of cases). Geographic distribu-
tion remained fairly constant, with highest representation from the South (~30% of 
cases) and West (~30% of cases). ConClusions: Pediatric MD incidence declined 
during the 2000’s, possibly due to the introduction of the meningococcal conjugate 
vaccine in 2005. However, MD incidence remained substantially higher in infants 
compared with other age groups and there appeared to be a demographic shift in 
cases away from females and whites.
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objeCtives: To identify and understand hepatitis C virus (HCV) prevalence and 
mortality rates, disease course, and the availability of data on patient and viral 
characteristics that may affect treatment and outcomes. Methods: A targeted 
review was undertaken in MEDLINE, using a predefined search strategy, to identify 
studies describing HCV burden. Additional searches were performed on the ISPOR 
conference and key epidemiological websites. Results: A total of 1,773 references 
were identified. Results indicated that global HCV prevalence increased from 2.3% 
to 2.8% between 1990 and 2005, with highest prevalence in East Asia (> 3.5%). HCV 
screening programmes and mandatory reporting are present in only a few countries, 
so prevalence is likely to be even greater. In 2010, there were estimated to be 499,000 
deaths globally related to HCV, making HCV-related complications the 25th most 
common cause of death and a significant global health problem. The prevalence 
of HCV genotypes varies geographically. Genotype 1 is most prevalent in North 
and South America, Europe, and the Asia-Pacific region (~45%-80%). Genotype 3 is 
most prevalent in South Asia (Pakistan, India, and Thailand) (~52%-80%); genotype 
4 is most prevalent in the Middle East (~60%-92%). There is a lack of data for the 
majority of African and some Middle Eastern countries. Genotype 1 is associated 
with increased insulin resistance, worse response to therapy, and higher risk of 
developing cirrhosis and hepatocellular carcinoma. Genotype 3 is associated with 
increased steatosis (up to 73% of patients vs. 51% in patients with other genotypes) 
and fibrosis. ConClusions: In light of upcoming treatment alternatives, detailed 
epidemiological studies will help ascertain more accurately the prevalence of each 
HCV genotype, so that the true burden of HCV can be understood and treatments 
targeted appropriately.
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objeCtives: Varicella is a common and vaccine-preventable disease, but its impact 
on public health in Eastern Europe (EE) has received little attention. This study aimed 
to review the epidemiology and economic burden of varicella in EE. Methods: A 
systematic literature review was conducted in PubMed and government websites 
to identify published data on epidemiology and economic burden of varicella in EE. 
Extracted study data included varicella incidence, complications, mortality, vac-
cination program availability and coverage rates, as well as health care resource 
utilization and medical costs associated with varicella. Critical analyses of study 
quality and data gaps were analyzed at the country level. Results: Published 
varicella data were identified from fourteen countries including Bosnia Herzegovina, 
Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, 
Romania, Russia, Serbia, Slovakia, and Slovenia. Only Latvia has a universal vari-
cella vaccination program, while the remaining countries either only recommend 
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objeCtives: Estimates assume that 400,000 to 500,000 people are chronically 
infected with Hepatitis C in Germany. About 27% of end-stage liver cirrhosis and 
25% of hepatocellular carcinoma are associated with HCV. The economic relevance 
of hepatitis C results from high costs for antiviral treatment as well as accom-
panying and secondary diseases. The aim of the study was to gain information 
on epidemiological characteristics, treatment outcomes and costs. Methods: 
Underlying data were collected in a non-interventional trial between 2008 and 
2011. Inclusion criteria were a confirmed HCV diagnosis and need for antivi-
ral treatment. Besides sociodemographic and clinical parameters, HCV related 
resource utilization was gathered for a subgroup of patients. Data presented are 
mean values. Results: Data on 7,637 patients receiving antiviral treatment with 
peginterferon-α -2a and ribavirin were collected. This analysis relates on 3,708 
patients without HIV coinfection and/or drug substitution treatment. Mean age 
was 43.7 years, 60.3% were male. Most patients had a genotype-1 (61.3%) or geno-
type-3 infection (28.5%). The majority of patients was treatment-naïve (86.5%), 
7.3% were relapser and 5.6% non-responder. Main sources of infection were injec-
tion drug use (34.8%) and blood products (14.2%). Mean duration of infection was 
13.6 years. In average 48.9% of treatment-naïve GT-1(4-6) and 63.0% of GT-2/3 
patients achieved SVR. For prior relapse patients and non-responder SVR-rates 
were: GT-1(4-6): 35.4%; GT-2/3: 58.5 and GT-1(4-6): 23.3% GT-2/3: 37.9%, respectively. 
Costs for antiviral treatment amount for € 20,889 in GT-1(4-6) patients and € 13,610 
in GT-2/3 patients. Costs for the management of adverse events or HCV-related 
diseases sum up for € 11.70. Ambulatory care, diagnostics procedures and hospi-
tal care amount for a small proportion of total costs. ConClusions: This study 
provides an overview on epidemiologic characteristics, treatment outcomes and 
treating costs in routine care. Treatment of HCV is costly and mainly affected by 
length of antiviral therapy.
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objeCtives: To estimate the number of cases of nosocomial skin and soft tissue 
infection (SSTIs) in adults caused by Gram-positive bacteria (GPB) in public hospi-
tals in Mexico. Methods: The total number of hospital discharges in patients ≥ 18 
years were extracted from databases of the National Health Information System. 
A rate of 5.97 cases of nosocomial infection (NI) per 100 discharges (issued by 
Instituto Mexicano del Seguro Social between 2011 and 2012) was applied. Through 
a systematic literature review and critical reading of studies developed under 
the Mexican setting (using the Critical Appraisal Skills Programme guidelines), 
we assessed the type of infection and determined the proportions of: microbio-
logical culture obtained and microbiological culture giving positive isolates. In 
the last stage, microorganisms were classified according to their Gram stain-
ing characteristics. Results: In the year 2011 there were 5,517,139 discharges 
from public hospital, inferring 329,373 cases of NI rate (16.9% under 18 years and 
83.1% in adults). We estimated that SSTIs represents 33.2% of NI (42,430 cases), of 
these, a microbiological culture was obtained only in 63.0% of the cases (26,731) 
and pathogen were isolated in 87.0% of microbiological cultures (23,256), among 
these, GPB was identified in 44.2%. According to our estimates a conservative 
number of cases of nosocomial SSTis in adults caused by GPB in 2011 was 10,279 
and the pathogens reported were Staphylococcus aureus (71.1%), Enterococcus spp 
(14.2%), and others (14.6%). ConClusions: Although we found high heterogeneity 
in NI reports which may decrease the quality of the estimates presented in this 
research, in our opinion these results could help clinicians in the choice of initial 
antibiotics in order to reduce the probability of failure due emergence of resist-
ant organisms.
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objeCtives: Chronic hepatitis C (CHC) treatment aims to prevent end-stage liver 
disease (ESLD) through sustained viral response (SVR). Treatment rates differ sig-
nificantly across Europe (< 1-16%). New protease-inhibitor based therapy offers an 
opportunity for increased SVR rates versus pegylated-interferon/ribavirin (> 70% 
vs. 50%). The analysis estimates the impact of various treatment rates on future 
ESLD sequelae associated with genotype-1 CHC in the UK. Methods: A Markov 
model was applied to estimate disease progression of a cohort of genotype-1 CHC 
patients over a 20-year time horizon. Endpoints included the following ESLD states: 
decompensated cirrhosis (DCC), hepatocellular carcinoma (HCC), liver transplan-
tation (LT) and liver-related death (LrD). Model structure, progression rates, CHC 
prevalence and disease severity at baseline were based on published economic 
evaluations. The number of ESLD cases averted by a 1-year increase in the current 
UK treatment rate (3%) to 12% and 16% was estimated for a 71.5% and 50.0% SVR 
rate. Results: Applying a 3% treatment rate and 71.5%/50.0% SVR rate predicted 
8590/8647 cumulative DCC and 3577/3595 HCC cases, 814/820 LTs and 7613/7659 
LrDs. The number of ESLD cases averted by applying a 12% treatment rate was 
estimated to be 565/395 DCC and 180/126 HCC cases, 51/36 LTs and 453/317 LrDs. 
